3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Radiation Fibrosis Syndrome
2
Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Pancreatic Adenocarcinoma
1
Inflammation
1
Fibrosis
1
Fallopian Tube Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Camurati-Engelmann Syndrome
1
Interventions
Gemcitabine
58
130-nm albumin-bound paclitaxel
35
Specimen Handling
26
Fluorouracil
22
Albumin-Bound Paclitaxel
22
Magnetic Resonance Spectroscopy
21
Leucovorin
21
Irinotecan
21
Oxaliplatin
19
Biopsy
17
Taxes
16
pembrolizumab
15
Cyclophosphamide
12
Cisplatin
11
fludarabine
10
Cetuximab
9
Capecitabine
8
durvalumab
7
Radiosurgery
7
Nivolumab
7
Carboplatin
7
irinotecan sucrosofate
6
dehydroftorafur
6
Pemetrexed
6
olaparib
5
Radiotherapy
5
Ipilimumab
5
Erlotinib Hydrochloride
5
Blood Specimen Collection
5
trastuzumab deruxtecan
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Losartan
×
90 days
×
Clear all
NCT04106856
2026-05-12
SHAPER
University of Utah
Phase 1
Active not recruiting
22 enrolled